21st International Conference on Emergency Medicine 2022

14 – 19 June

Hybrid Conference I Melbourne Convention and Exhibition Centre

21st International Conference on Emergency Medicine

14 – 19 June 2022

Hybrid Conference
Melbourne Convention and Exhibition Centre

21st International Conference on Emergency Medicine 2022

14 – 19 June

Hybrid Conference I Melbourne Convention and Exhibition Centre
PARTNER PROGRAM SPONSOR
12:30 – 1:30PM
THURSDAY 16 JUNE

LUNCH & LEARN SESSION 1

POC high sensitivity troponin: Is there a role in the ED?

The use of a point-of-care, high-sensitivity cardiac troponin assay in the Emergency Department to assist in the early diagnosis of myocardial infarction: clinical considerations, economic impact and future opportunities.

Chair:  Prof Louise Cullen

Speakers:  

Access block in ED, future forecast, Dr Martin Than

Analytical performance of the VTLi hs-cTnI assay, Prof Richard Body

The value of time, current assays in the market, Dr Frank Peacock

Speaker: Dr Martin Than

With a career in medicine spanning 30 years, Dr Than has been an Emergency Medicine Specialist in Christchurch, New Zealand since 2001. For the past 15 years he has undertaken significant research projects, with a focus on knowledge translation that makes meaningful clinical impact. He is  Director of Emergency Medicine Research in Christchurch Hospital and has been awarded multiple grants by the New Zealand  Health Research Council  including a 5-year Clinical Practitioner Research Fellowship.

Dr Than has participated in many committees and advisory boards including the IFCC Committee on the Clinical Application of Cardiac Biomarkers that created the definition of high sensitivity troponin.

Dr Than’s profound interest in supporting and monitoring research that improves patient care safely and ethically drives him to participate in any forums with aligned aims. He has extensive international collaborative links and experience in undertaking and overseeing large research projects.

Dr Than has led the Christchurch-based research team that has undertaken a series of projects since 2007 that have  changed practice across NZ hospitals and many others world-wide. The team’s projects have involved 6 major studies which have been recognised with local and international awards, most recently the 2020 International UNIVANTS of Healthcare Excellence award.

He has published 172 papers and 3 book chapters to date.

Speaker: Prof Rick Body

MB ChB, MRCSEd(A&E), FRCEM, PhD

Prof Body is a Professor of Emergency Medicine at the University of Manchester. He is also an Honorary Consultant in Emergency Medicine and the Group Director of Research & Innovation at Manchester University NHS Foundation. Prof Body is Deputy Editor at the Emergency Medicine Journal, Deputy National Specialty Lead for Trauma & Emergency Care at the NIHR National Institute of Health Research and a member of the International Federation of Clinical Chemistry Committee for Cardiac Biomarkers. His research focuses on analytical modeling, decision support, diagnostics and the design and conduct of large clinical studies. Prof. Body’s work on high-sensitivity cardiac troponin assays for early diagnosis of acute coronary syndromes has led to a number of high impact publications and widespread changes to clinical practice internationally.

Speaker: Dr Frank Peacock

MD, FACEP, FACC, FESC

Dr. Peacock is Vice Chair for Research, Henry JN Taub Department of Emergency Medicine, Baylor College of Medicine in Houston, Texas. With over 600 publications on heart failure and acute coronary syndromes, Dr. Peacock is also the co-editor of the textbooks Cardiac Emergencies, Short Stay Management of Heart Failure, and Short Stay Management of Chest Pain. He is the 2004 and 2010 winner of the Best Research Paper Award from the American College of Emergency Physicians, the winner of the 2019 Ray Bahr Award for Excellence from the American College of Cardiology and is the Codman Award recipient from the American Association of Group Practice.

Dr. Peacock has and continues to serve as PI or co-PI for many high profile national and international clinical trials such as PRONTO, ADHERE-EM, IMPACT, CHOPIN, CLUE, FASTTRACK and TRUE-HF. His clinical interests and research focus include acute coronary syndrome, acute heart failure, biomarkers, improvements in emergency medical care, and more rapid patient disposition.

Speaker: Prof Louise Cullen

MBBS(HON), FACEM, Ph.D.

Louise Cullen is an Emergency Physician in Brisbane, Australia, a clinical trialist and outcomes researcher in acute diseases, holding the position of Professor at the University of Queensland and Adjunct Professor at Queensland University of Technology. She is enthusiastically involved in the translation of research by clinical redesign and innovation. As an accomplished acute disease research, Prof. Cullen has focused on the diagnosis and management of patients presenting with possible acute coronary syndrome (ACS)  the emergency department (ED). She has been engaged in many international collaborations and has authored over 150 publications in peer-reviewed journals including the NEJM and the Lancet, focused on strategies to improve efficiency, whilst maintaining safety for patients with possible ACS, syncope, heart failure, shortness of breath and atrial fibrillation. More recently, Prof. Cullen has focused on health services research aimed at reducing unnecessary or low benefit care in the ED.

Atellica® VTLi Patient-side Immunoassay Analyzer

A vital leap forward in cardiac testing

When a patient enters the emergency department presenting with the symptoms of a myocardial infarction (MI), every moment is critical. Achieving favourable clinical and operational outcomes requires fast and accurate chest pain assessment at the point of care, as well as coordination with the laboratory for quality assurance. Having high-sensitivity troponin testing at the point of care—producing accurate results in just 8 minutes—could transform care delivery for millions of people each year, improving ED throughput, reducing stress and strain on acute care clinicians, and aiding in optimizing the use of time and resources of busy laboratories.

Vyaire Medical Inc. is a global company, headquartered in suburban Chicago, focused exclusively on supporting breathing through every stage of life. Established from legacy brands with a 65-year history of pioneering breathing technology, the company’s portfolio of integrated solutions is designed to enable, enhance, and extend lives.

At Vyaire, our team of 4000, pledges to advance innovation and evolve what’s possible to ensure every breath is taken to its fullest. Vyaire’s products are available in more than 100 countries and are recognized, trusted, and preferred by specialists throughout the respiratory community worldwide.

Vyaire has a long and proud history with emergency care throughout Australia and beyond. As the home of legacy brands including Vital Signs, AirLife, enFlow, GreenLight, bellavista, and many more, we are your trusted partner every step in delivering emergency care.

Come speak to Vyaire to learn more about our innovative solutions in ventilation and respiratory care, and blood and fluid management in the ED.

COMPANY

Insert Bio

NAME

Face placeholder

Insert Title

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.